Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Petros Pharmaceuticals, Inc. (PTPI)

Compare
0.0691
-0.0169
(-19.65%)
At close: 4:00:01 PM EDT
0.0709
+0.00
+(2.60%)
After hours: 6:13:13 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PTPI

Recent News: PTPI

View More

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
ACCESS Newswire 11 days ago

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
ACCESS Newswire last month

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
ACCESS Newswire last month

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
ACCESS Newswire 2 months ago

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
ACCESS Newswire 3 months ago

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
ACCESS Newswire 3 months ago
Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. 4 months ago
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESS Newswire 6 months ago
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ACCESS Newswire 6 months ago
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
Simply Wall St. 7 months ago
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESS Newswire 7 months ago
View More

Related Tickers

QNTM Quantum BioPharma Ltd.
7.71
-9.93%
 
RGC Regencell Bioscience Holdings Limited
31.88
+24.19%
 
TLRY Tilray Brands, Inc.
0.6575
-0.78%
 
UPC Universe Pharmaceuticals INC
4.1000
-16.16%
 
CGC Canopy Growth Corporation
0.9100
-7.67%
 
ZYBT Zhengye Biotechnology Holding Limited
5.38
+5.39%
 
ACB Aurora Cannabis Inc.
4.3900
-0.90%
 
TEVA Teva Pharmaceutical Industries Limited
15.37
+1.92%
 
CTOR Citius Oncology, Inc.
0.9300
+39.85%
 
SNOA Sonoma Pharmaceuticals, Inc.
2.1900
-9.13%